RAF1 and melanoma: The frequent mutational activation of BRAF in melanoma [23] led to the development of type I small molecule inhibitors to inhibit the constitutive activity of the most common RAF variant in cancer, BRAFV600E, which is active as a monomer in contrast with wild-type RAF which signals as a dimer.